Gilead fires back in ongoing battle with HHS, suing the government for ‘secretly’ obtaining patents
While the world urgently awaits data on their potential coronavirus drug, Gilead continues to duke it out with the government over a life-saving drug for a different plague.
On Friday, the California-based drugmaker filed a lawsuit accusing the CDC of breaking longstanding agreements by “secretly” obtaining patents on Gilead’s pre-exposure prophylaxis HIV drug Truvada and failing to notify the company for nearly a decade. The allegations relate to four material transfer agreements, or MTAs, under which Gilead provided drugs to the CDC for academic research and for clinical trials in Botswana. Those MTAs, Gilead says, required the government to disclose any inventions arising out of that research.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.